Annis Gardner Whiting Capital Advisors, LLC Bei Gene, Ltd. Transaction History

Annis Gardner Whiting Capital Advisors, LLC

$355 Billion
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 13, 2024	BUY	$141.8 - $181.47 $5,104 - $6,532	36 New	36 $5.63 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.89 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.15 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$927 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$891 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$664 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Annis Gardner Whiting Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Annis Gardner Whiting Capital Advisors, LLC with notifications on news.

Account